Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant

PURPOSETo report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex(®); Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis. METHODSA retrospective chart review of patients with noninfectious uveitis treated with sustained-release dexamethasone 0.7 mg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical ophthalmology (Auckland, N.Z.) N.Z.), 2010, Vol.4, p.1423-1426
Hauptverfasser: Myung, Jane S, Aaker, Grant D, Kiss, Szilárd
Format: Report
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1426
container_issue
container_start_page 1423
container_title Clinical ophthalmology (Auckland, N.Z.)
container_volume 4
creator Myung, Jane S
Aaker, Grant D
Kiss, Szilárd
description PURPOSETo report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex(®); Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis. METHODSA retrospective chart review of patients with noninfectious uveitis treated with sustained-release dexamethasone 0.7 mg intravitreal implant was performed. Complete ophthalmic examination including signs of inflammatory activity, visual acuity, fundus photography, fluorescein angiography, optical coherence tomography, and tolerability of the implant were assessed. RESULTSSix eyes of 4 consecutive patients treated with a total of 8 dexamethasone 0.7 mg sustained-release intravitreal implants for posterior noninfectious uveitis were included. Two patients presented with unilateral idiopathic posterior uveitis; 2 patients had bilateral posterior uveitis, one secondary to sarcoidosis and the other to Vogt-Koyanagi-Harada syndrome. All eyes showed clinical and angiographic evidence of decreased inflammation following implant placement. Mean follow-up time post-injection was 5.25 months. Four eyes received 1 and 2 eyes received 2 Ozurdex implants during the follow-up period. The duration of effect of the implant was 3 to 4 months. No serious ocular or systemic adverse events were noted during the follow-up period. CONCLUSIONSIn patients with noninfectious posterior uveitis, sustained-release dexamethasone 0.7 mg intravitreal implant may be an effective treatment option for controlling intraocular inflammation.
doi_str_mv 10.2147/OPTH.S15696
format Report
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_821596370</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>821596370</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_8215963703</originalsourceid><addsrcrecordid>eNqNjbsKwjAUQIMg-Jz8gWxOatJX6iyKm4LdJegtvdImNfdW_Xw7-AFOZzmcI8RCq3WkE7M5nYvj-qLTbJsNxFhrY1ZpkscjMSF6KJVFKjdjURQBLDfgWPpSOu_QlXBj9B3J1hNDQB9k9wJkJPlGruQdPrYBrix5BxIdB_tC7jO1xKatreOZGJa2Jpj_OBXLw77YHVdt8M8OiK8N0g3q3oV-dM0jnW6z2Kj4f_MLHjJJ3w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype><pqid>821596370</pqid></control><display><type>report</type><title>Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant</title><source>DOAJ Directory of Open Access Journals</source><source>Dove Press Free</source><source>PubMed Central Open Access</source><source>Access via Taylor &amp; Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Myung, Jane S ; Aaker, Grant D ; Kiss, Szilárd</creator><creatorcontrib>Myung, Jane S ; Aaker, Grant D ; Kiss, Szilárd</creatorcontrib><description>PURPOSETo report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex(®); Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis. METHODSA retrospective chart review of patients with noninfectious uveitis treated with sustained-release dexamethasone 0.7 mg intravitreal implant was performed. Complete ophthalmic examination including signs of inflammatory activity, visual acuity, fundus photography, fluorescein angiography, optical coherence tomography, and tolerability of the implant were assessed. RESULTSSix eyes of 4 consecutive patients treated with a total of 8 dexamethasone 0.7 mg sustained-release intravitreal implants for posterior noninfectious uveitis were included. Two patients presented with unilateral idiopathic posterior uveitis; 2 patients had bilateral posterior uveitis, one secondary to sarcoidosis and the other to Vogt-Koyanagi-Harada syndrome. All eyes showed clinical and angiographic evidence of decreased inflammation following implant placement. Mean follow-up time post-injection was 5.25 months. Four eyes received 1 and 2 eyes received 2 Ozurdex implants during the follow-up period. The duration of effect of the implant was 3 to 4 months. No serious ocular or systemic adverse events were noted during the follow-up period. CONCLUSIONSIn patients with noninfectious posterior uveitis, sustained-release dexamethasone 0.7 mg intravitreal implant may be an effective treatment option for controlling intraocular inflammation.</description><identifier>EISSN: 1177-5483</identifier><identifier>DOI: 10.2147/OPTH.S15696</identifier><language>eng</language><ispartof>Clinical ophthalmology (Auckland, N.Z.), 2010, Vol.4, p.1423-1426</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784,864,4490,27925</link.rule.ids></links><search><creatorcontrib>Myung, Jane S</creatorcontrib><creatorcontrib>Aaker, Grant D</creatorcontrib><creatorcontrib>Kiss, Szilárd</creatorcontrib><title>Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant</title><title>Clinical ophthalmology (Auckland, N.Z.)</title><description>PURPOSETo report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex(®); Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis. METHODSA retrospective chart review of patients with noninfectious uveitis treated with sustained-release dexamethasone 0.7 mg intravitreal implant was performed. Complete ophthalmic examination including signs of inflammatory activity, visual acuity, fundus photography, fluorescein angiography, optical coherence tomography, and tolerability of the implant were assessed. RESULTSSix eyes of 4 consecutive patients treated with a total of 8 dexamethasone 0.7 mg sustained-release intravitreal implants for posterior noninfectious uveitis were included. Two patients presented with unilateral idiopathic posterior uveitis; 2 patients had bilateral posterior uveitis, one secondary to sarcoidosis and the other to Vogt-Koyanagi-Harada syndrome. All eyes showed clinical and angiographic evidence of decreased inflammation following implant placement. Mean follow-up time post-injection was 5.25 months. Four eyes received 1 and 2 eyes received 2 Ozurdex implants during the follow-up period. The duration of effect of the implant was 3 to 4 months. No serious ocular or systemic adverse events were noted during the follow-up period. CONCLUSIONSIn patients with noninfectious posterior uveitis, sustained-release dexamethasone 0.7 mg intravitreal implant may be an effective treatment option for controlling intraocular inflammation.</description><issn>1177-5483</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2010</creationdate><recordtype>report</recordtype><recordid>eNqNjbsKwjAUQIMg-Jz8gWxOatJX6iyKm4LdJegtvdImNfdW_Xw7-AFOZzmcI8RCq3WkE7M5nYvj-qLTbJsNxFhrY1ZpkscjMSF6KJVFKjdjURQBLDfgWPpSOu_QlXBj9B3J1hNDQB9k9wJkJPlGruQdPrYBrix5BxIdB_tC7jO1xKatreOZGJa2Jpj_OBXLw77YHVdt8M8OiK8N0g3q3oV-dM0jnW6z2Kj4f_MLHjJJ3w</recordid><startdate>20101206</startdate><enddate>20101206</enddate><creator>Myung, Jane S</creator><creator>Aaker, Grant D</creator><creator>Kiss, Szilárd</creator><scope>7X8</scope></search><sort><creationdate>20101206</creationdate><title>Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant</title><author>Myung, Jane S ; Aaker, Grant D ; Kiss, Szilárd</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_8215963703</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2010</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Myung, Jane S</creatorcontrib><creatorcontrib>Aaker, Grant D</creatorcontrib><creatorcontrib>Kiss, Szilárd</creatorcontrib><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Myung, Jane S</au><au>Aaker, Grant D</au><au>Kiss, Szilárd</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant</atitle><jtitle>Clinical ophthalmology (Auckland, N.Z.)</jtitle><date>2010-12-06</date><risdate>2010</risdate><volume>4</volume><spage>1423</spage><epage>1426</epage><pages>1423-1426</pages><eissn>1177-5483</eissn><abstract>PURPOSETo report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex(®); Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis. METHODSA retrospective chart review of patients with noninfectious uveitis treated with sustained-release dexamethasone 0.7 mg intravitreal implant was performed. Complete ophthalmic examination including signs of inflammatory activity, visual acuity, fundus photography, fluorescein angiography, optical coherence tomography, and tolerability of the implant were assessed. RESULTSSix eyes of 4 consecutive patients treated with a total of 8 dexamethasone 0.7 mg sustained-release intravitreal implants for posterior noninfectious uveitis were included. Two patients presented with unilateral idiopathic posterior uveitis; 2 patients had bilateral posterior uveitis, one secondary to sarcoidosis and the other to Vogt-Koyanagi-Harada syndrome. All eyes showed clinical and angiographic evidence of decreased inflammation following implant placement. Mean follow-up time post-injection was 5.25 months. Four eyes received 1 and 2 eyes received 2 Ozurdex implants during the follow-up period. The duration of effect of the implant was 3 to 4 months. No serious ocular or systemic adverse events were noted during the follow-up period. CONCLUSIONSIn patients with noninfectious posterior uveitis, sustained-release dexamethasone 0.7 mg intravitreal implant may be an effective treatment option for controlling intraocular inflammation.</abstract><doi>10.2147/OPTH.S15696</doi></addata></record>
fulltext fulltext
identifier EISSN: 1177-5483
ispartof Clinical ophthalmology (Auckland, N.Z.), 2010, Vol.4, p.1423-1426
issn 1177-5483
language eng
recordid cdi_proquest_miscellaneous_821596370
source DOAJ Directory of Open Access Journals; Dove Press Free; PubMed Central Open Access; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central
title Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T01%3A17%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Treatment%20of%20noninfectious%20posterior%20uveitis%20with%20dexamethasone%20intravitreal%20implant&rft.jtitle=Clinical%20ophthalmology%20(Auckland,%20N.Z.)&rft.au=Myung,%20Jane%20S&rft.date=2010-12-06&rft.volume=4&rft.spage=1423&rft.epage=1426&rft.pages=1423-1426&rft.eissn=1177-5483&rft_id=info:doi/10.2147/OPTH.S15696&rft_dat=%3Cproquest%3E821596370%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=821596370&rft_id=info:pmid/&rfr_iscdi=true